# Study of Olutasidenib and Temozolomide in HGG

> **NCT06161974** · PHASE2 · RECRUITING · sponsor: **Rigel Pharmaceuticals** · enrollment: 60 (estimated)

## Conditions studied

- High Grade Glioma
- Astrocytoma
- Astrocytoma, Grade III
- Astrocytoma, Grade IV
- Diffuse Intrinsic Pontine Glioma
- WHO Grade III Glioma
- WHO Grade IV Glioma
- Metastatic Brain Tumor
- Diffuse Midline Glioma, H3 K27M-Mutant
- Thalamus Tumor
- Spinal Tumor
- IDH1 Mutation
- IDH1 R132
- IDH1 R132C
- IDH1 R132H
- IDH1 R132S
- IDH1 R132G
- IDH1 R132L
- Oligodendroglioma

## Interventions

- **DRUG:** Olutasidenib + TMZ

## Key facts

- **NCT ID:** NCT06161974
- **Lead sponsor:** Rigel Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03
- **Primary completion:** 2029-06
- **Final completion:** 2035-06
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-02-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06161974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06161974, "Study of Olutasidenib and Temozolomide in HGG". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06161974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*